文献速递免疫规划慢病防控与筛查

免疫介导炎症性疾病患者新冠疫苗基础免疫与加强免疫的免疫原性:免疫抑制治疗的影响

Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy.
PubMed 文献 · Vaccine · 2025-12-23

本研究基于丹麦ENFORCE队列,纳入282例免疫介导炎症性疾病(IMID)患者和482例免疫正常对照,随访两年评估新冠疫苗基础免疫及加强免疫的免疫原性。结果显示,接受抗CD20抗体或芬戈莫德治疗的IMID患者第90天血清转化率显著降低、抗体水平显著更低且疫苗低反应风险显著增高,该受损应答持续至随访结束;而甲氨蝶呤、TNF-α抑制剂或其他免疫抑制剂治疗的患者能产生有效疫苗应答。

要点

  • 抗CD20抗体或芬戈莫德治疗者新冠疫苗血清转化率和抗体水平显著降低。
  • 上述患者疫苗低反应风险显著增高且加强接种后仍无法达到对照水平。
  • 甲氨蝶呤、TNF-α抑制剂或其他免疫抑制剂治疗者疫苗应答良好。

核心结论

  • 抗CD20抗体和芬戈莫德严重损害IMID患者体液疫苗应答,而甲氨蝶呤、TNF-α抑制剂或其他免疫抑制剂治疗者能产生有效应答。

研究设计与样本

  • 基于丹麦ENFORCE队列的前瞻性随访研究,纳入282例IMID患者和482例免疫正常对照,随访两年。

主要发现

  • 第90天,抗CD20抗体治疗者血清转化率27%、芬戈莫德治疗者60%,对照为100%。
  • 第90天,抗CD20抗体治疗者抗体水平2251 AU/mL(95%CI 888-5703),芬戈莫德治疗者1743 AU/mL(95%CI 784-3873),对照为186308 AU/mL(95%CI 171366-202552)。
  • 疫苗低反应(Spike IgG较基线升高<2log10)的OR分别为67.5(95%CI 25.4-179.7)和82.5(95%CI 29.6-196.3)。
  • 受损应答持续整个随访期,反复加强接种后抗体滴度仍无法达到对照第90天水平。

临床怎么用

  • 对接受抗CD20抗体或芬戈莫德治疗的IMID患者,应考虑早期和频繁加强接种的定制疫苗方案以保护该高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with immune-mediated inflammatory diseases (IMID) are at increased risk of severe COVID-19 infection. Their immunosuppressive treatment may lead to attenuated vaccine responses. In this study, we assessed the impact of specific immunosuppressive treatments on the immunogenicity of primary SARS-CoV-2 vaccination as well as booster vaccinations in IMID patients. MATERIAL AND METHODS: We included participants with IMID from the Danish ENFORCE cohort with baseline sampling prior to SARS-CoV-2 vaccination. Participants were followed for two years, with scheduled visits prior to vaccine dose 2, day 90, 180, 365 and 730 as well as before and after each booster dose. At all visits, seroconversion rates and quantitative SARS-CoV-2 Spike IgG antibody levels were assessed. Vaccine hyporesponsiveness, defined as <2log10 increase in SARS-CoV-2 Spike IgG levels from baseline, was evaluated at day 90 and again after the first booster. RESULTS: We included 282 patients with IMID and 482 immunocompetent controls. At day 90, patients with IMID treated with anti-CD20 antibodies or fingolimod exhibited markedly reduced seroconversion rates (27 % and 60 %, respectively, vs 100 % for controls), significantly lower antibody levels (2251 AU/mL [95 % CI: 888-5703] and 1743 AU/mL [95 % CI:784-3873] vs 186,308 AU/mL [95 % CI, 171366-202,552]) and higher odds of vaccine hyporesponsiveness (odds ratio (OR) = 67.5 [95 % CI, 25.4-179.7] and 82.5 [95 % CI, 29.6-196.3]). This impaired response persisted throughout the follow-up period, and anti-CD20 antibodies and fingolimod treated patients never reached antibody titers comparable to day 90 titers in controls, despite repeated booster vaccinations. CONCLUSION: Anti-CD20 antibody treatment and fingolimod severely impair humoral vaccine responses in IMID patients. In contrast, IMID patients treated with Methotrexate, TNF-alpha inhibitors, or other immunosuppressants mounted efficient vaccine responses. These findings support that tailored vaccine schedules with early and frequent boosters are crucial to protect this high-risk population. CLINICAL TRIAL REGISTRATION: EudraCT no, 2020-006003-42, NVK no. 1-10-72-337-20.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Larsen FD, Juhl AK, Dietz LL, et al. Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy. Vaccine. 2025. PMID: 41442865. doi:10.1016/j.vaccine.2025.128155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。